Updated: Novartis rejigs late-stage plans for Cosentyx, next-gen CAR-T, TIGIT antibody and more
Novartis has cleaned up its Phase III slate, shelving late-stage plans for programs across inflammatory diseases and cancer, the Swiss pharma giant disclosed in its quarterly update — while also putting a mid-stage Huntington’s drug to bed and switching things up for a key rare disease candidate.
The biggest change came in the decision to abandon a Phase III trial for Cosentyx, Novartis’ blockbuster IL-17A antibody, in active peripheral spondyloarthritis. It didn’t end up recruiting any of the 324 patients planned before terminating the trial earlier this month due to a “strategic decision of senior management,” according to records on clinicaltrials.gov.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.